First Test Launched, Theranostics Focuses on Reimbursements as it Builds …

whether individual patients will respond to certain breast cancer therapies, and in addition to measuring HER2, EGFR, and HER3 levels, it measures three important breast cancer pathways — the JAK-STAT pathway involved in inflammatory breast cancer




http://ift.tt/eA8V8J

0 comments:

Post a Comment